
Cretostimogene Cuts Recurrence Risk by 68% in Intermediate-Risk NMIBC
Key Takeaways
- Cretostimogene demonstrated a clinically meaningful RFS advantage over surveillance after TURBT, meeting the phase 3 primary endpoint with HR 0.32 and P < .0001.
- Safety was favorable, with no grade ≥3 treatment-related adverse events and no treatment-related discontinuations reported at the October 2026 data cutoff.
Adjuvant cretostimogene reduced recurrence risk vs surveillance after resection in the phase 3 PIVOT-006 trial in intermediate-risk and high-grade Ta NMIBC (HR, 0.32).
Adjuvant intravesical cretostimogene grenadenorepvec, an oncolytic viral therapy, improved recurrence-free survival (RFS) compared with surveillance in patients with intermediate-risk and high-grade stage Ta non–muscle invasive bladder cancer (NMIBC) after complete tumor resection.1
In the randomized phase 3 PIVOT-006 trial (NCT06111235), cretostimogene lowered the risk of recurrence by 68% vs surveillance (HR, 0.32; 95% CI, 0.23-0.45; P < .0001) at a median follow-up of 17 months, meeting its primary end point at a data cutoff of October 26, 2026. No grade 3 or higher treatment-related adverse events (TRAEs) or treatment-related discontinuations occurred.
“For patients with intermediate-risk and high-grade Ta NMIBC, reducing recurrence is a meaningful clinical objective because recurrence can bring additional invasive procedures and continued disease burden,” said Vijay Kasturi, MD, chief medical officer of CG Oncology, in a news release.1
Trial Design
A total of 367 patients enrolled at approximately 90 US and Canadian sites. Patients were randomly assigned 1:1 after transurethral resection of bladder tumor to cretostimogene or to surveillance alone. Those in the cretostimogene arm received an induction course followed by quarterly maintenance courses through month 13 in the absence of recurrence. Patients in the surveillance arm who developed recurrent disease during the course of the trial were offered treatment with cretostimogene. Secondary end points were RFS at 12 and 24 months, and incidence of adverse events for up to 34 months.2
Eligible tumors spanned the intermediate-risk categories in American Urological Association/Society of Urologic Oncology guidelines at the time the study began: low-grade Ta recurring within 12 months, solitary low-grade Ta larger than 3 cm, multifocal low-grade Ta, solitary high-grade Ta measuring 3 cm or smaller, and low-grade T1 disease. According to CG Oncology, no adjuvant therapy is FDA approved for this population, which the company estimates to be approximately 50,000 patients in the United States.1
CG Oncology, the sponsor, stated that the benefit was observed in both high-grade and low-grade disease.1 Full results will be presented as a late-breaking abstract on December 2, 2026, at the Society of Urologic Oncology (SUO) Annual Meeting in San Diego, California.1
Next Steps
The company stated its intention to submit a biologics license application (BLA) based on PIVOT-006 in the second quarter of 2027. Additionally, following FDA feedback, CG Oncology will expand its first BLA, which was granted in Bacillus Calmette–Guérin vaccine (BCG)-unresponsive NMIBC, to cover high-grade papillary-only disease in addition to carcinoma in situ with or without papillary tumors, with submission now expected by the end of March 2027.
That initial filing is supported by the phase 3 BOND-003 trial (NCT04452591), in which
In an interim analysis of 66 patients presented at the 2023 SUO Annual Meeting, the complete response rate at any time was 75.7% (95% CI, 63%-85%), and no grade 3 or higher TRAEs were reported among 112 treated patients.3 In the BCG-unresponsive setting, the FDA has granted cretostimogene both fast track and breakthrough therapy designations.
“Together, these populations represent the full range of BCG-unresponsive patients, and our goal is a label that reflects that,” said Arthur Kuan, MS, chairman, president, and chief executive officer of CG Oncology, in the news release.1
REFERENCES
1. PIVOT-006 phase 3 registrational trial demonstrates unprecedented improvement in recurrence-free survival (RFS) for intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC). News release. CG Oncology. November 16, 2026. Accessed November 16, 2026. [URL]
2. A study of adjuvant cretostimogene grenadenorepvec for treatment of intermediate risk NMIBC following TURBT. ClinicalTrials.gov. Updated July 1, 2026. https://clinicaltrials.gov/study/NCT06111235
3. Tyson M, Uchio E, Jong-Kil N, et al. First results from BOND-003, a phase 3 study of intravesical cretostimogene grenadenorepvec monotherapy for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer. Presented at: 24th Annual Meeting of the Society of Urologic Oncology. November 28-December 1, 2023; Washington, DC. LBA3396.
Related to this article








